Last reviewed · How we verify
low dose budesonide tablet
Low dose budesonide tablets, marketed by Dr. Falk Pharma GmbH, hold a significant position in the treatment of specific gastrointestinal conditions. The drug's key strength lies in its well-established safety and efficacy profile, supported by its current market availability. The primary risk to consider is the key composition patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | low dose budesonide tablet |
|---|---|
| Also known as | BET 1mg BID |
| Sponsor | Dr. Falk Pharma GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis (PHASE4)
- The Treatment of Moderate to Severe Allergic Rhinitis With Electroacupuncture Combined With Microneedle Knife (NA)
- Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis (PHASE2)
- The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis (PHASE4)
- Asthma Control in Elderly Patients With Montelukast (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- low dose budesonide tablet CI brief — competitive landscape report
- low dose budesonide tablet updates RSS · CI watch RSS
- Dr. Falk Pharma GmbH portfolio CI